

Table 4.26

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	287,321	99.4%	231,745	99.4%	30,532	99.3%	21,283	99.3%	1,138	99.3%	28,427	99.2%
Epidermoid carcinoma ^d (8051-8131)	137	0.0%	112	0.0%	18	0.1%	-	-	-	-	-	-
Adenocarcinoma ^e	281,422	97.4%	227,241	97.5%	29,570	96.2%	20,945	97.7%	1,109	96.8%	27,799	97.0%
Adenocarcinoma, NOS (8140)	2,270	0.8%	1,778	0.8%	297	1.0%	144	0.7%	-	-	239	0.8%
Infiltrating duct carcinoma (8500)	210,966	73.0%	168,328	72.2%	23,155	75.3%	16,705	78.0%	879	76.7%	21,128	73.8%
Lobular carcinoma, NOS (8520)	25,603	8.9%	22,003	9.4%	2,143	7.0%	1,144	5.3%	75	6.5%	2,098	7.3%
Inflammatory adenocarcinoma (8530)	1,055	0.4%	812	0.3%	182	0.6%	47	0.2%	-	-	145	0.5%
Infiltrating duct mixed and infiltrating lobular mixed (8522-8524)	27,154	9.4%	22,931	9.8%	2,224	7.2%	1,686	7.9%	85	7.4%	2,824	9.9%
Mucinous adenocarcinoma (8480,8482)	5,850	2.0%	4,589	2.0%	600	2.0%	576	2.7%	23	2.0%	519	1.8%
Mucin-producing adenocarcinoma (8481)	69	0.0%	51	0.0%	-	-	-	-	-	-	-	-
Tubular adenocarcinoma (8211)	2,051	0.7%	1,830	0.8%	119	0.4%	92	0.4%	-	-	151	0.5%
Papillary adenocarcinoma (8050,8260,8503,8504)	1,689	0.6%	1,203	0.5%	286	0.9%	183	0.9%	-	-	183	0.6%
Paget disease (8540-8543)	1,352	0.5%	1,075	0.5%	144	0.5%	111	0.5%	-	-	156	0.5%
Other adenocarcinomas ^f	3,363	1.2%	2,641	1.1%	408	1.3%	252	1.2%	-	-	349	1.2%
Other specific carcinomas ^g	2,420	0.8%	1,802	0.8%	464	1.5%	125	0.6%	-	-	294	1.0%
Medullary adenocarcinoma (8510-8513)	876	0.3%	590	0.3%	229	0.7%	48	0.2%	-	-	143	0.5%
Other ^h	1,544	0.5%	1,212	0.5%	235	0.8%	77	0.4%	-	-	151	0.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	3,342	1.2%	2,590	1.1%	480	1.6%	207	1.0%	17	1.5%	320	1.1%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Other adenocarcinomas include histologies 8141-8147, 8160-8162, 8180-8210, 8212-8221, 8250-8259, 8261-8479, 8483-8499, 8501-8502, 8505-8507, 8514, 8521, 8525-8529, 8531-8539, 8544-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas include histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^h Other includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.26 - continued

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 9040-9044,9120-9136, 9150-9252,9370-9373, 9540-9582)	324	0.1%	256	0.1%	39	0.1%	25	0.1%	-	-	24	0.1%
Hemangiosarcomas (9120-9126,9170)	165	0.1%	142	0.1%	-	-	-	-	-	-	-	-
Other sarcomas ^d	159	0.1%	114	0.0%	29	0.1%	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	736	0.3%	554	0.2%	87	0.3%	86	0.4%	-	-	133	0.5%
Phyllodes tumor, malignant (9020)	614	0.2%	463	0.2%	63	0.2%	81	0.4%	-	-	116	0.4%
Other ^e	122	0.0%	91	0.0%	24	0.1%	-	-	-	-	17	0.1%
Unspecified (8000-8005)	638	0.2%	483	0.2%	92	0.3%	34	0.2%	-	-	62	0.2%
Total ^f	289,019	100.0%	233,038	100.0%	30,750	100.0%	21,428	100.0%	1,146	100.0%	28,646	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Other sarcomas include histologies 8680-8713, 8800-8921, 9040-9044, 9127-9136, 9150-9169, 9171-9252, 9370-9373, 9540-9582.

^e Other includes histologies 8720-8790, 8930-8936, 8950-9019, 9021-9030, 9060-9110, 9260-9365, 9380-9539.

^f Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.27

Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma ^d	73,901	99.8%	58,202	99.8%	7,667	99.7%	6,873	100.0%	231	100.0%	6,603	99.9%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> ^f	62,662	84.6%	48,798	83.7%	6,728	87.5%	6,225	90.5%	197	85.3%	5,641	85.3%
Cribiform carcinoma <i>in situ</i> (8201/2)	6,254	8.4%	4,764	8.2%	700	9.1%	676	9.8%	21	9.1%	591	8.9%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	4,819	6.5%	3,891	6.7%	426	5.5%	440	6.4%	-	-	385	5.8%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	23,004	31.1%	18,193	31.2%	2,508	32.6%	1,959	28.5%	65	28.1%	2,009	30.4%
Comedocarcinoma <i>in situ</i> (8501/2)	5,867	7.9%	4,613	7.9%	596	7.8%	568	8.3%	33	14.3%	525	7.9%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,183	1.6%	810	1.4%	205	2.7%	142	2.1%	-	-	109	1.6%
Noninfiltrating intracystic carcinoma(8504/2)	293	0.4%	190	0.3%	44	0.6%	54	0.8%	-	-	28	0.4%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,448	2.0%	1,146	2.0%	174	2.3%	106	1.5%	-	-	129	2.0%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	19,612	26.5%	15,052	25.8%	2,063	26.8%	2,251	32.7%	55	23.8%	1,848	27.9%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	8,436	11.4%	7,161	12.3%	670	8.7%	397	5.8%	26	11.3%	725	11.0%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	8,410	11.4%	7,139	12.2%	666	8.7%	397	5.8%	26	11.3%	725	11.0%
Lobular CIS ^f with other CIS ^f (8524/2)	25	0.0%	22	0.0%	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	2,326	3.1%	1,883	3.2%	221	2.9%	187	2.7%	-	-	195	2.9%
Other adenocarcinomas ^g	470	0.6%	354	0.6%	48	0.6%	63	0.9%	-	-	42	0.6%
Other <i>in situ</i> histologies ^h	154	0.2%	126	0.2%	23	0.3%	-	-	-	-	-	-
Total	74,055	100.0%	58,328	100.0%	7,690	100.0%	6,875	100.0%	231	100.0%	6,612	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

^f CIS = Carcinoma *in situ*.

^g Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

^h Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 5.16

Cancer of the Cervix Uteri (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	16,600	98.1%	12,493	98.2%	2,319	97.6%	1,425	98.3%	123	98.4%	3,646	98.3%
Epidermoid carcinoma ^d (8050-8131)	11,187	66.1%	8,155	64.1%	1,843	77.5%	946	65.3%	78	62.4%	2,530	68.2%
Squamous cell carcinoma (8070)	7,649	45.2%	5,502	43.2%	1,351	56.8%	626	43.2%	56	44.8%	1,563	42.1%
Squamous cell, keratinizing (8071)	1,202	7.1%	874	6.9%	199	8.4%	109	7.5%	-	-	317	8.5%
Squamous cell, non-keratinizing (8072)	1,508	8.9%	1,147	9.0%	196	8.2%	140	9.7%	-	-	429	11.6%
Squamous cell, Microinvasive (8076)	567	3.4%	433	3.4%	59	2.5%	50	3.5%	-	-	157	4.2%
Other (8050-8069, 8073-8075,8077-8131)	261	1.5%	199	1.6%	38	1.6%	21	1.4%	-	-	64	1.7%
Adenocarcinoma ^e	4,678	27.6%	3,811	30.0%	354	14.9%	420	29.0%	36	28.8%	953	25.7%
Adenocarcinoma, NOS (8140)	2,453	14.5%	2,007	15.8%	176	7.4%	217	15.0%	-	-	501	13.5%
Adenosquamous (8560,8570)	621	3.7%	484	3.8%	64	2.7%	61	4.2%	-	-	146	3.9%
Other adenocarcinomas ^f	1,604	9.5%	1,320	10.4%	114	4.8%	142	9.8%	-	-	306	8.3%
Other specific carcinomas ^g	249	1.5%	191	1.5%	32	1.3%	21	1.4%	-	-	55	1.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	486	2.9%	336	2.6%	90	3.8%	38	2.6%	-	-	108	2.9%
Sarcoma ^h	61	0.4%	45	0.4%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	163	1.0%	113	0.9%	32	1.3%	16	1.1%	-	-	27	0.7%
Unspecified (8000-8005)	97	0.6%	73	0.6%	-	-	-	-	-	-	22	0.6%
Total	16,921	100.0%	12,724	100.0%	2,377	100.0%	1,449	100.0%	125	100.0%	3,709	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Other adenocarcinomas include histologies 8141-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8571-8574,8576,8940-8941.

^g Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8175,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

^h Sarcoma includes histologies 8680-8713,8800-8921,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	182,283	99.5%	143,653	99.5%	21,610	99.4%	14,060	99.4%	922	99.2%	17,847	99.4%
Epidermoid carcinoma ^d (8051-8131)	1,056	0.6%	893	0.6%	125	0.6%	21	0.1%	-	-	79	0.4%
Squamous cell carcinoma (8070-8078,8083-8084)	1,004	0.5%	848	0.6%	120	0.6%	21	0.1%	-	-	73	0.4%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8520-8551,8560, 8570-8574,8576,8940-8941)	171,165	93.4%	136,032	94.2%	19,651	90.4%	13,059	92.4%	861	92.7%	16,631	92.6%
Adenocarcinoma, NOS (8140)	117,304	64.0%	92,859	64.3%	13,628	62.7%	9,305	65.8%	631	67.9%	11,416	63.6%
Adenocarcinoma in adenomatous polyp (8210)	15,066	8.2%	11,912	8.2%	1,572	7.2%	1,243	8.8%	76	8.2%	1,336	7.4%
Adenocarcinoma in villous adenoma (8261)	4,845	2.6%	3,916	2.7%	517	2.4%	344	2.4%	21	2.3%	589	3.3%
Mucinous adenocarcinoma (8470-8473,8480,8482)	11,753	6.4%	9,705	6.7%	1,246	5.7%	690	4.9%	46	5.0%	1,204	6.7%
Mucin-producing adenocarcinoma (8481)	2,119	1.2%	1,716	1.2%	288	1.3%	108	0.8%	-	-	187	1.0%
Signet ring adenocarcinoma (8490)	1,967	1.1%	1,625	1.1%	177	0.8%	145	1.0%	-	-	200	1.1%
Other adenocarcinomas ^e	18,111	9.9%	14,299	9.9%	2,223	10.2%	1,224	8.7%	75	8.1%	1,699	9.5%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	8,419	4.6%	5,454	3.8%	1,630	7.5%	859	6.1%	42	4.5%	983	5.5%
Neuroendocrine carcinoid (8240-8245)	6,670	3.6%	4,071	2.8%	1,411	6.5%	746	5.3%	34	3.7%	819	4.6%
Other ^f	1,749	1.0%	1,383	1.0%	219	1.0%	113	0.8%	-	-	164	0.9%
Unspecified, Carcinoma, NOS (8010-8011, 8020-8022)	1,643	0.9%	1,274	0.9%	204	0.9%	121	0.9%	18	1.9%	154	0.9%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Includes histologies 8050, 8141-8147, 8160-8162, 8180-8204, 8211-8221, 8250-8260, 8262-8264, 8270-8463, 8500-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8231, 8246-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29 - continued

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	107	0.1%	89	0.1%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	287	0.2%	201	0.1%	48	0.2%	37	0.3%	-	-	36	0.2%
Unspecified (8000-8005)	606	0.3%	457	0.3%	65	0.3%	37	0.3%	-	-	62	0.3%
Total ^d	183,283	100.0%	144,400	100.0%	21,735	100.0%	14,138	100.0%	929	100.0%	17,960	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 8.22

Cancer of the Esophagus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	18,386	99.1%	15,427	99.1%	1,974	99.1%	791	99.2%	76	100.0%	1,306	98.9%
Epidermoid carcinoma ^d (8051-8131)	6,246	33.7%	4,028	25.9%	1,599	80.3%	556	69.8%	28	36.8%	505	38.2%
Squamous cell carcinoma (8070-8078, 8083-8084)	6,229	33.6%	4,016	25.8%	1,594	80.0%	556	69.8%	28	36.8%	504	38.2%
Adenocarcinoma ^e	11,269	60.7%	10,660	68.5%	298	15.0%	198	24.8%	43	56.6%	739	55.9%
Other specific carcinomas ^f	275	1.5%	230	1.5%	31	1.6%	-	-	-	-	16	1.2%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	596	3.2%	509	3.3%	46	2.3%	28	3.5%	-	-	46	3.5%
Other specific types ^g	50	0.3%	41	0.3%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	117	0.6%	99	0.6%	-	-	-	-	-	-	-	-
Total	18,553	100.0%	15,567	100.0%	1,992	100.0%	797	100.0%	76	100.0%	1,321	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma is defined as histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas is defined as histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^h Other specific types includes sarcomas and other soft tissue tumors.

ⁱ Other specific types is defined as histologies 8680-8713, 8720-8790, 8800-8921, 8930-8936, 8950-9030, 9040-9044, 9060-9110, 9120-9136, 9150-9252, 9260-9365, 9370-9373, 9380-9539, 9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 14.22

Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma (8010-8576)	21,869	97.2%	15,329	96.9%	2,818	98.3%	3,364	97.8%	195	96.1%	3,507	95.3%
Hepatocellular carcinoma ^d (8170-8175)	16,940	75.3%	11,527	72.9%	2,381	83.1%	2,743	79.7%	154	75.9%	2,805	76.2%
Cholangiocarcinoma (8032-8033,8070-8071, 8140-8141,8160,8260, 8480-8481,8490,8560)	3,936	17.5%	3,095	19.6%	325	11.3%	465	13.5%	31	15.3%	541	14.7%
Other carcinoma ^e	993	4.4%	707	4.5%	112	3.9%	156	4.5%	-	-	161	4.4%
Other specific carcinoma ^f	598	2.7%	434	2.7%	59	2.1%	98	2.8%	-	-	96	2.6%
Unspecified, Carcinoma, NOS (8010,8020-8022,8031, 8046,8050)	395	1.8%	273	1.7%	53	1.8%	58	1.7%	-	-	65	1.8%
Hepatoblastoma (8970)	213	0.9%	168	1.1%	-	-	25	0.7%	-	-	83	2.3%
Sarcoma ^g	204	0.9%	160	1.0%	18	0.6%	23	0.7%	-	-	37	1.0%
Hemangiosarcoma (9120)	81	0.4%	66	0.4%	-	-	-	-	-	-	-	-
Other sarcomas ^h	123	0.5%	94	0.6%	-	-	-	-	-	-	24	0.7%
Other specific types (8720,8980,8991,9061, 9064,9070-9071,9080, 9100)	40	0.2%	28	0.2%	-	-	-	-	-	-	-	-
Unspecified (8000-8004)	165	0.7%	129	0.8%	-	-	21	0.6%	-	-	43	1.2%
Total ^d	22,492	100.0%	15,815	100.0%	2,866	100.0%	3,440	100.0%	203	100.0%	3,680	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma arising from liver parenchyma are referred to as hepatocellular carcinoma.

^e Other carcinoma include histologies 8010, 8012-8013, 8020-8022, 8031, 8035, 8041-8042, 8046, 8050, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

^f Other specific carcinoma include histologies 8012-8013, 8035, 8041-8042, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

^g Sarcoma includes histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9120, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

^h Other sarcomas include histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.28

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Both Sexes by Race

Histology ^a	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	53.1	226,636	99.7%	187,403	99.7%	25,035	99.7%	12,606	99.7%	750	99.1%	12,439	99.4%
Small cell (8002,8041-8045)	7.0	30,407	13.4%	26,559	14.1%	2,640	10.5%	997	7.9%	136	18.0%	1,441	11.5%
Non-small cell	44.3	188,975	83.2%	155,008	82.5%	21,484	85.6%	11,158	88.3%	589	77.8%	10,463	83.6%
Squamous and transitional cell ^d	11.9	50,017	22.0%	41,875	22.3%	5,847	23.3%	1,939	15.3%	183	24.2%	2,322	18.6%
Adenocarcinoma ^e	22.0	94,257	41.5%	76,348	40.6%	10,283	41.0%	7,024	55.6%	225	29.7%	5,512	44.1%
Large cell ^f	1.2	5,261	2.3%	4,289	2.3%	717	2.9%	222	1.8%	17	2.2%	248	2.0%
Non-small cell carcinoma ^g	6.7	28,578	12.6%	23,140	12.3%	3,659	14.6%	1,523	12.1%	135	17.8%	1,574	12.6%
Other specified carcinomas ^h	2.5	10,862	4.8%	9,356	5.0%	978	3.9%	450	3.6%	29	3.8%	807	6.5%
Carcinoma, NOS ⁱ	1.7	7,254	3.2%	5,836	3.1%	911	3.6%	451	3.6%	25	3.3%	535	4.3%
Sarcoma ^j	0.1	422	0.2%	338	0.2%	48	0.2%	25	0.2%	-	-	50	0.4%
Other specified types ^k	0.0	184	0.1%	151	0.1%	25	0.1%	-	-	-	-	22	0.2%
Total	53.2	227,242	100.0%	187,892	100.0%	25,108	100.0%	12,639	100.0%	757	100.0%	12,511	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^e Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^f Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^g Non-small cell carcinoma includes histology 8046.

^h Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

ⁱ Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^j Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.29

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Males by Race

Histology ^a	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	63.6	120,359	99.7%	98,209	99.7%	14,094	99.8%	7,177	99.7%	402	99.3%	6,649	99.4%
Small cell (8002,8041-8045)	7.8	15,186	12.6%	13,078	13.3%	1,348	9.5%	659	9.2%	64	15.8%	769	11.5%
Non-small cell	53.6	101,107	83.8%	81,932	83.2%	12,198	86.3%	6,232	86.6%	325	80.2%	5,571	83.3%
Squamous and transitional cell ^d	16.9	31,503	26.1%	26,077	26.5%	3,762	26.6%	1,424	19.8%	111	27.4%	1,489	22.3%
Adenocarcinoma ^e	24.0	45,578	37.8%	36,429	37.0%	5,380	38.1%	3,471	48.2%	111	27.4%	2,620	39.2%
Large cell ^f	1.5	2,952	2.4%	2,384	2.4%	413	2.9%	136	1.9%	-	-	150	2.2%
Non-small cell carcinoma ^g	8.5	16,069	13.3%	12,831	13.0%	2,139	15.1%	950	13.2%	80	19.8%	925	13.8%
Other specified carcinomas ^h	2.6	5,005	4.1%	4,211	4.3%	504	3.6%	251	3.5%	-	-	387	5.8%
Carcinoma, NOS ⁱ	2.2	4,066	3.4%	3,199	3.2%	548	3.9%	286	4.0%	-	-	309	4.6%
Sarcoma ^j	0.1	227	0.2%	186	0.2%	23	0.2%	-	-	-	-	24	0.4%
Other specified types ^k	0.1	114	0.1%	97	0.1%	-	-	-	-	-	-	-	-
Total	63.8	120,700	100.0%	98,492	100.0%	14,128	100.0%	7,195	100.0%	405	100.0%	6,687	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^e Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^f Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^g Non-small cell carcinoma includes histology 8046.

^h Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

ⁱ Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^j Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.30

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Females by Race

Histology ^a	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	45.2	106,277	99.8%	89,194	99.8%	10,941	99.6%	5,429	99.7%	348	98.9%	5,790	99.4%
Small cell (8002,8041-8045)	6.5	15,221	14.3%	13,481	15.1%	1,292	11.8%	338	6.2%	72	20.5%	672	11.5%
Non-small cell	37.4	87,868	82.5%	73,076	81.7%	9,286	84.6%	4,926	90.5%	264	75.0%	4,892	84.0%
Squamous and transitional cell ^d	8.0	18,514	17.4%	15,798	17.7%	2,085	19.0%	515	9.5%	72	20.5%	833	14.3%
Adenocarcinoma ^e	20.7	48,679	45.7%	39,919	44.7%	4,903	44.7%	3,553	65.3%	114	32.4%	2,892	49.7%
Large cell ^f	1.0	2,309	2.2%	1,905	2.1%	304	2.8%	86	1.6%	-	-	98	1.7%
Non-small cell carcinoma ^g	5.3	12,509	11.7%	10,309	11.5%	1,520	13.8%	573	10.5%	55	15.6%	649	11.1%
Other specified carcinomas ^h	2.5	5,857	5.5%	5,145	5.8%	474	4.3%	199	3.7%	16	4.5%	420	7.2%
Carcinoma, NOS ⁱ	1.3	3,188	3.0%	2,637	2.9%	363	3.3%	165	3.0%	-	-	226	3.9%
Sarcoma ^j	0.1	195	0.2%	152	0.2%	25	0.2%	-	-	-	-	26	0.4%
Other specified types ^k	0.0	70	0.1%	54	0.1%	-	-	-	-	-	-	-	-
Total	45.4	106,542	100.0%	89,400	100.0%	10,980	100.0%	5,444	100.0%	352	100.0%	5,824	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^e Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^f Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^g Non-small cell carcinoma includes histology 8046.

^h Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

ⁱ Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^j Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 20.28

Cancer of the Oral Cavity and Pharynx (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
All Races, Both Sexes, by site

Histology ^a	Oral Cavity and Pharynx		Lip		Tongue		Salivary Gland		Floor of Mouth	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	40,374	84.0%	2,723	94.4%	13,790	97.1%	1,182	21.9%	2,436	95.5%
Squamous cell carcinoma (8070-8078,8083-8084)	39,392	82.0%	2,616	90.7%	13,572	95.6%	1,128	20.9%	2,413	94.6%
Adenocarcinoma ^c	4,962	10.3%	116	4.0%	224	1.6%	3,307	61.3%	88	3.4%
Other specific carcinomas ^d	527	1.1%	-	-	42	0.3%	302	5.6%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	1,619	3.4%	-	-	87	0.6%	404	7.5%	-	-
Sarcoma and soft tissue ^e	162	0.3%	-	-	17	0.1%	35	0.6%	-	-
Other specific types ^f	225	0.5%	-	-	-	-	99	1.8%	-	-
Unspecified (8000-8005)	169	0.4%	-	-	30	0.2%	70	1.3%	-	-
Total	48,038	100.0%	2,884	100.0%	14,202	100.0%	5,399	100.0%	2,551	100.0%

Histology ^a	Gum and Other Mouth		Nasopharynx		Oropharynx and Tonsil		Hypopharynx		Other Oral Cavity and Pharynx	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	5,208	80.4%	1,757	63.1%	9,856	97.2%	2,697	96.7%	725	89.1%
Squamous cell carcinoma (8070-8078,8083-8084)	4,957	76.6%	1,588	57.0%	9,733	96.0%	2,670	95.7%	715	87.8%
Adenocarcinoma ^c	1,032	15.9%	90	3.2%	69	0.7%	18	0.6%	18	2.2%
Other specific carcinomas ^d	40	0.6%	48	1.7%	45	0.4%	20	0.7%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	64	1.0%	822	29.5%	137	1.4%	40	1.4%	40	4.9%
Sarcoma and soft tissue ^e	35	0.5%	39	1.4%	-	-	-	-	-	-
Other specific types ^f	77	1.2%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	18	0.3%	16	0.6%	18	0.2%	-	-	-	-
Total	6,474	100.0%	2,786	100.0%	10,138	100.0%	2,790	100.0%	814	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^c Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^d Other specific carcinomas includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^e Sarcoma and soft tissue includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

^f Other specific types includes histologies 8720-8790, 8930-8936, 8950-8983, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	24,578	91.7%	20,563	92.2%	1,912	88.3%	1,824	90.3%	116	92.8%	2,859	87.3%
Epidermoid carcinoma ^d (8051-8131)	191	0.7%	149	0.7%	18	0.8%	21	1.0%	-	-	28	0.9%
Adenocarcinoma ^e	22,524	84.0%	18,946	84.9%	1,650	76.2%	1,680	83.1%	105	84.0%	2,560	78.1%
Adenocarcinoma, NOS (8140)	3,291	12.3%	2,679	12.0%	403	18.6%	183	9.1%	-	-	323	9.9%
Papillary adenocarcinoma, NOS (8050,8260)	404	1.5%	350	1.6%	34	1.6%	-	-	-	-	47	1.4%
Clear cell adenocarcinoma (8310,9110)	1,407	5.2%	1,089	4.9%	51	2.4%	257	12.7%	-	-	146	4.5%
Endometrioid carcinoma (8380-8383,8570)	2,593	9.7%	2,186	9.8%	121	5.6%	245	12.1%	-	-	353	10.8%
Cystadenocarcinoma, NOS (8440,8450)	110	0.4%	88	0.4%	-	-	-	-	-	-	-	-
Serous cystadenocarcinoma (8441)	5,601	20.9%	4,798	21.5%	383	17.7%	346	17.1%	35	28.0%	593	18.1%
Papillary serous cystadenocarcinoma (8460-8462)	6,307	23.5%	5,435	24.4%	463	21.4%	357	17.7%	30	24.0%	699	21.3%
Mucinous cystadenocarcinoma (8470-8473)	403	1.5%	332	1.5%	29	1.3%	35	1.7%	-	-	66	2.0%
Mucinous adenocarcinoma (8480,8482)	949	3.5%	756	3.4%	80	3.7%	101	5.0%	-	-	137	4.2%
Mucin-producing adenocarcinoma(8481)	48	0.2%	39	0.2%	-	-	-	-	-	-	-	-
Other adenocarcinoma ^f	1,411	5.3%	1,194	5.4%	64	3.0%	133	6.6%	-	-	174	5.3%
Other specific carcinomas ^g	617	2.3%	448	2.0%	120	5.5%	37	1.8%	-	-	103	3.1%
Stromal cell tumor (8620-8631,8650)	425	1.6%	294	1.3%	97	4.5%	22	1.1%	-	-	70	2.1%
Other ^h	192	0.7%	154	0.7%	23	1.1%	-	-	-	-	33	1.0%
Unspecified, Carcinoma, NOS (8010,8020-8022)	1,246	4.6%	1,020	4.6%	124	5.7%	86	4.3%	-	-	168	5.1%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.

^g Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449,8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.

^h Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Other subgroup of other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16 - continued

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582)	96	0.4%	66	0.3%	20	0.9%	-	-	-	-	20	0.6%
Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539)	1,852	6.9%	1,452	6.5%	204	9.4%	168	8.3%	-	-	361	11.0%
Mullerian mixed tumor (8950-8951,8980)	806	3.0%	674	3.0%	73	3.4%	49	2.4%	-	-	65	2.0%
Teratoma, malignant (9080-9085,9102)	411	1.5%	296	1.3%	54	2.5%	54	2.7%	-	-	146	4.5%
Other	635	2.4%	482	2.2%	77	3.6%	65	3.2%	-	-	150	4.6%
Unspecified (8000-8005)	286	1.1%	232	1.0%	29	1.3%	19	0.9%	-	-	36	1.1%
Total ^d	26,812	100.0%	22,313	100.0%	2,165	100.0%	2,021	100.0%	125	100.0%	3,276	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 22.22

Cancer of the Pancreas (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	41,388	97.9%	33,185	97.9%	5,005	97.9%	2,825	97.8%	182	99.5%	4,038	97.5%
Epidermoid carcinoma ^d (8051-8131)	92	0.2%	70	0.2%	-	-	-	-	-	-	-	-
Adenocarcinoma ^e	36,359	86.0%	29,209	86.2%	4,358	85.3%	2,474	85.6%	158	86.3%	3,509	84.7%
Adenocarcinoma, NOS (8140)	29,528	69.9%	23,692	69.9%	3,614	70.7%	1,954	67.6%	137	74.9%	2,872	69.3%
Papillary adenocarcinoma, NOS (8260)	49	0.1%	40	0.1%	-	-	-	-	-	-	-	-
Mucinous adenocarcinoma (8480,8482)	1,096	2.6%	889	2.6%	119	2.3%	75	2.6%	-	-	106	2.6%
Mucin-producing adenocarcinoma (8481)	444	1.1%	365	1.1%	52	1.0%	25	0.9%	-	-	36	0.9%
Infiltrating duct carcinoma (8500-8503,8507,8514)	4,157	9.8%	3,361	9.9%	433	8.5%	337	11.7%	-	-	350	8.4%
Other adenocarcinoma ^f	1,085	2.6%	862	2.5%	135	2.6%	79	2.7%	-	-	138	3.3%
Other specific carcinomas ^g	2,749	6.5%	2,211	6.5%	314	6.1%	195	6.7%	-	-	280	6.8%
Islet cell carcinoma (8150-8155)	361	0.9%	302	0.9%	34	0.7%	22	0.8%	-	-	32	0.8%
Other carcinomas ^h	2,388	5.7%	1,909	5.6%	280	5.5%	173	6.0%	-	-	248	6.0%
Unspecified, "Carcinoma, NOS" (8010,8020-8022)	2,189	5.2%	1,696	5.0%	319	6.2%	150	5.2%	-	-	244	5.9%
Sarcoma and other soft tissue tumors ⁱ	30	0.1%	24	0.1%	-	-	-	-	-	-	-	-
Other specific types ^j	35	0.1%	26	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	809	1.9%	645	1.9%	94	1.8%	62	2.1%	-	-	96	2.3%
Total	42,264	100.0%	33,881	100.0%	5,112	100.0%	2,890	100.0%	183	100.0%	4,143	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Other adenocarcinoma include histologies 8050,8141-8147,8160-8162,8180-8221,8250-8259,8261-8479,8483-8499,8504-8506,8520-8551,8560,8570-8574,8576,8940-8941.

^g Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

^h Other carcinomas include histologies 8012-8015,8030-8046,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Sarcoma and other soft tissue tumors include histologies 8680-8713,8800-8921,8990-8991,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

^j Other specific types include histologies 8720-8790,8930-8936,8950-9030,9060-9110,9260-9365,9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	28,948	93.3%	20,670	93.8%	3,873	89.3%	3,965	94.6%	208	95.9%	5,116	95.8%
Epidermoid carcinoma ^d (8051-8131)	271	0.9%	195	0.9%	47	1.1%	25	0.6%	-	-	25	0.5%
Squamous cell carcinoma (8070-8078,8083-8084)	262	0.8%	189	0.9%	46	1.1%	23	0.5%	-	-	21	0.4%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8514,8520-8551, 8560,8570-8574, 8576,8940-8941)	25,967	83.6%	18,439	83.6%	3,437	79.2%	3,741	89.2%	185	85.3%	4,583	85.8%
Adenocarcinoma, NOS (8140)	14,993	48.3%	11,049	50.1%	1,969	45.4%	1,795	42.8%	97	44.7%	2,252	42.2%
Adenocarcinoma, intestinal type (8144)	2,601	8.4%	1,548	7.0%	389	9.0%	619	14.8%	27	12.4%	487	9.1%
Carcinoma, diffuse type (8145)	1,089	3.5%	676	3.1%	136	3.1%	259	6.2%	-	-	235	4.4%
Linitus plastica (8142)	196	0.6%	151	0.7%	20	0.5%	22	0.5%	-	-	55	1.0%
Mucinous adenocarcinoma (8470-8473,8480,8482)	427	1.4%	309	1.4%	67	1.5%	47	1.1%	-	-	73	1.4%
Mucin-producing adenocarcinoma (8481)	170	0.5%	128	0.6%	28	0.6%	-	-	-	-	24	0.4%
Signet ring adenocarcinoma (8490)	5,212	16.8%	3,703	16.8%	673	15.5%	755	18.0%	41	18.9%	1,223	22.9%
Other adenocarcinomas ^e	1,279	4.1%	875	4.0%	155	3.6%	230	5.5%	-	-	234	4.4%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	1,944	6.3%	1,502	6.8%	268	6.2%	106	2.5%	-	-	384	7.2%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	766	2.5%	534	2.4%	121	2.8%	93	2.2%	-	-	124	2.3%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Other adenocarcinomas includes histologies 8050, 8141, 8143, 8146-8147, 8160-8162, 8180-8221, 8250-8469, 8474-8479, 8483-8489, 8491-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22 - continued

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	78	0.3%	58	0.3%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	1,868	6.0%	1,212	5.5%	433	10.0%	203	4.8%	-	-	182	3.4%
Unspecified (8000-8005)	148	0.5%	106	0.5%	17	0.4%	20	0.5%	-	-	31	0.6%
Total ^d	31,043	100.0%	22,047	100.0%	4,337	100.0%	4,192	100.0%	217	100.0%	5,339	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 26.22

Cancer of the Thyroid (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2007-2011
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	55,363	99.7%	45,207	99.7%	3,633	99.5%	5,401	99.7%	232	100.0%	8,037	99.7%
Epidermoid carcinoma ^d (8051-8131)	54	0.1%	43	0.1%	-	-	-	-	-	-	-	-
Adenocarcinoma ^e	53,495	96.3%	43,682	96.3%	3,468	94.9%	5,254	97.0%	226	97.4%	7,797	96.7%
Papillary adenocarcinoma (8050,8260,8340-8344, 8350,8450)	48,857	87.9%	40,016	88.2%	2,955	80.9%	4,894	90.3%	204	87.9%	7,246	89.9%
Follicular carcinoma (8330-8332,8335)	3,060	5.5%	2,361	5.2%	368	10.1%	262	4.8%	16	6.9%	385	4.8%
Oxyphilic (8290)	1,280	2.3%	1,078	2.4%	108	3.0%	73	1.3%	-	-	135	1.7%
Other specific carcinomas ^f	1,017	1.8%	847	1.9%	97	2.7%	51	0.9%	-	-	139	1.7%
Medullary carcinoma (8510)	985	1.8%	819	1.8%	93	2.5%	51	0.9%	-	-	134	1.7%
Carcinoma, NOS (8004,8010-8012, 8020-8022,8030-8032)	797	1.4%	635	1.4%	63	1.7%	90	1.7%	-	-	95	1.2%
Anaplastic carcinoma (8004,8012,8020-8021, 8030-8032)	486	0.9%	392	0.9%	31	0.8%	60	1.1%	-	-	54	0.7%
Sarcoma and other soft tissue tumors ^g	-	-	-	-	-	-	-	-	-	-	-	-
Other specific types ^h	-	-	-	-	-	-	-	-	-	-	-	-
Unspecified (8000-8003,8005)	170	0.3%	130	0.3%	16	0.4%	17	0.3%	-	-	22	0.3%
Total	55,554	100.0%	45,354	100.0%	3,653	100.0%	5,418	100.0%	232	100.0%	8,063	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas include histologies 8013-8015, 8033-8046, 8150-8155, 8170-8171, 8230-8249, 8510, 8512, 8561-8562, 8575, 8580-8671.

^h Sarcoma and other soft tissue tumors include histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

ⁱ Other specific types include histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.